AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02813291 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
Study NCT01883401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberries
Description: 25g or 50g freeze-dried strawberries reconstituted in water
Study NCT01883401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary fiber
Description: 4g or 8g dietary fiber blended in water
Study NCT01400867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
Study NCT01400867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam
Description: Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed
Study NCT01400867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin or Clindamycin or Linezolid
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
Study NCT01400867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin or Clindamycin or Linezolid
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
Study NCT03060434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline Oral Tablet
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
Study NCT03060434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
Study NCT03950128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Skills Training (MBST)
Description: This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well.
Study NCT03950128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational
Description: This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
Study NCT03001921 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
Study NCT01054703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethmoid Sinus Spacer
Description: Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
Study NCT02431858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Catheter (Pajunk)
Study NCT02431858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonolong Catheter (Pajunk)
Study NCT02340234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
Study NCT02340234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Study NCT04475874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supervised stretching exercises
Description: 30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
Study NCT04475874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-supervised active stretching home program
Description: non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
Study NCT00889824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balance prosthesis
Description: vibrotactile stimulation
Study NCT01669772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DA-9701 and placebo
Description: Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
Study NCT01669772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and DA-9701
Description: Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
Study NCT02363621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg
Description: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
Study NCT02363621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0 mg
Description: Patient will receive intravitreal injection of Aflibercept 2.0 mg
Study NCT02110667 — intervention group
Intervention type: DEVICE
Intervention: Transperineal Ultrasound
Study NCT02061514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance with desflurane
Description: in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
Study NCT02061514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance with propofol
Description: in patients allocated to the propofol group, general anesthesia will be maintained with propofol
Study NCT02199925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gammaplex 5%
Study NCT03357536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Skin biopsy~* Saliva
Study NCT00645021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with mild hepatic function
Study NCT00645021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with moderate hepatic function
Study NCT00645021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with normal hepatic function
Study NCT04236752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SBRT)
Study NCT02901418 — intervention group
Intervention type: BIOLOGICAL
Intervention: 200 IU HBIG
Description: additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
Study NCT03770221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH
Description: Brief, intensive case management service.
Study NCT03770221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CATCH
Description: Brief, intensive case management service.
Study NCT03770221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentive for maintaining contact with CATCH service providers.
Study NCT02586948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal CO2 removal (Hemolung device)
Description: ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
Study NCT02312050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1 mg, 3 mg, or 9 mg IV push injections
Study NCT02312050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04368715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser
Study NCT02196155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc..
Study NCT02196155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortisone
Study NCT02196155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT04425252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar
Description: DHODH inhibitor, 100 mg daily x 5 days
Study NCT04425252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care per institutional guidelines for COVID-19 patients
Study NCT03572348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transecting anastomotic repair (tAR)
Description: Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
Study NCT03572348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel-sparing anastomotic repair (vsAR)
Description: Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
Study NCT02382185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid optimisation
Description: The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
Study NCT02382185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimisation of blood pressure
Description: Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
Study NCT02382185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of clearsight monitor
Description: The clear sight monitor will be applied to measure stroke volume.
Study NCT01219751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg D1-D28 every 6 weeks
Study NCT03054194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: capsules
Study NCT03054194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study NCT04122820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic of specific learning disabilities or of Developmental Coordination Disorder
Description: Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
Study NCT00409006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
Study NCT00409006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
Study NCT00409006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
Study NCT03694210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRotor Therapy
Description: To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
Study NCT00628706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta9-tetrahydrocannabinol (THC)
Description: inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
Study NCT00628706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta9-tetrahydrocannabinol (THC)
Description: inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
Study NCT04025762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop system (CamAPS FX)
Description: Hybrid closed-loop system
Study NCT04025762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor augmented pump therapy
Description: Sensor augmented pump therapy
Study NCT04223323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
Study NCT04223323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pretzels
Description: Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
Study NCT00484198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45 mg over-encapsulated tablet administered orally, once daily
Study NCT00484198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
Study NCT00484198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone
Description: 1.0 mg tablet administered orally, once daily
Study NCT00484198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone
Description: 1.5 mg tablet administered orally, once daily
Study NCT03241121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
Study NCT03241121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular dietary advices
Description: Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
Study NCT03241121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eating patterns
Description: Data collection on eating patterns via the smartphone app
Study NCT03241121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eating patterns
Description: Data collection on eating patterns via the smartphone app
Study NCT02889172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
Study NCT04651426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1
Description: The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm.
Study NCT04651426 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1
Description: The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm.
Study NCT02837185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin injection
Description: Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
Study NCT02837185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological measures
Description: These include TMS and EMG measurements
Study NCT02837185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiological measures
Description: These include TMS and EMG measurements
Study NCT04047628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: 1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable.
Study NCT04047628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Solution, Oral, 100mg, Day 1 of Period 1
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Capsule, Oral, 2mg, Day 1 of Period 1
Study NCT01038167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Capsule, Oral, 0.5mg, Day 8 of Period 2